Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.41 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14674293 | 0.86 | ANPEP (0.54) | ANPEPGRIK1SLC1A2SLC1A1GRIK2 | |
| SCHEMBL10676946 | 0.82 | — | — | |
| SCHEMBL17434128 | 0.81 | PTGS1 (0.50) | GRIK1SLC1A2SLC1A1GRIK2SLC1A3 | |
| SCHEMBL19368124 | 0.81 | SLC1A2 (0.47) | ANPEPGRIK1SLC1A2SLC1A1GRIK2 | |
| SCHEMBL29951736 | 0.80 | PTGS1 (0.41) | GRIK1SLC1A2SLC1A1GRIK2SLC1A3 | |
| SCHEMBL8892460 | 0.80 | GSR (0.48) | GRIK1SLC1A2SLC1A1GRIK2SLC1A3 | |
| SCHEMBL28766764 | 0.80 | PTGS1 (0.41) | GRIK1SLC1A2SLC1A1GRIK2SLC1A3 | |
| SCHEMBL7270272 | 0.80 | GSR (0.50) | ANPEPGRIK1SLC1A2SLC1A1GRIK2 | |
| SCHEMBL5576905 | 0.80 | GSR (0.50) | ANPEPGRIK1SLC1A2SLC1A1GRIK2 | |
| SCHEMBL12643504 | 0.80 | GSR (0.50) | ANPEPGRIK1SLC1A2SLC1A1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
| US-7378386-B2 | Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | KIF5B, KIF23, KIF2C | ANPEP 3547/4885GRIK1 874/4885SLC1A2 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.